1. Scrip
  2. >>Therapy Areas

Panel backs GSK severe asthma drug in adults, not adolescents

 
• By Donna Young

GlaxoSmithKline won the full support of an FDA advisory panel on 11 June for the company's severe asthma drug mepolizumab as an add-on maintenance treatment in patients with eosinophilic inflammation.

GlaxoSmithKline won the full support of an FDA advisory panel on 11 June for the company's severe asthma drug mepolizumab as an add-on maintenance treatment in patients with eosinophilic inflammation.

But the committee said it could not endorse the use of the drug in adolescents 12-17 years because of a lack of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.